Overview

Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid

Status:
Unknown status
Trial end date:
2019-10-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy and safety of Sheng Bai oral liquid in prevention and treatment of the decrease of neutrophilics after chemotherapy in patients with non-small-cell lung cancer.
Phase:
N/A
Details
Lead Sponsor:
BeiJing Yijiayi Medicine Techonoloy Co., Ltd.
Collaborator:
Hubei Mon Yan Pharmaceutical Co., Ltd
Treatments:
Carboplatin
Cisplatin